Aeterna Zentaris Inc

Headquartered in Charleston, South Carolina, Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on developing and commercializing therapeutics and diagnostic tests. With a team of 37 employees, the company has generated $5.1 million in revenue. Aeterna Zentaris's lead product is Macrilen™ (macimorelin), an oral test approved by both the U.S. Food and Drug Administration and the European Commission for diagnosing adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a licensing agreement with Novo Nordisk, generating double-digit royalties for Aeterna Zentaris. The company retains complete ownership of Macrilen™ rights outside of the United States and Canada. Aeterna Zentaris is also exploring the use of Macrilen™ for diagnosing child-onset growth hormone deficiency (CGHD), a significant area of medical need. In addition to Macrilen™, Aeterna Zentaris is actively seeking business development opportunities to commercialize the product in Europe and other global regions. The company is also pursuing strategies to monetize its non-strategic assets. For more information about Aeterna Zentaris Inc. and its products, please visit their website at zentaris.com.